China is gaining a solid reputation as a pharmaceutical innovation hub, shifting from a copycat drug maker to one whose infrastructure and research and development capabilities rival global pharmaceutical behemoths, according to a global consultancy.
US-based SAI MedPartners and its unit Idea Pharma recently launched a new index with the aim of highlighting Chinese drug makers and recognising their shift from generics to “true” innovation.
The consultancy released the China Pharmaceutical…
TikTok Strikes Deal to Offload US Operations
...
Read moreDetails
